Zouari Raida, Hamden Khaled, El Feki Abdelfattah, Chaabouni Khansa, Makni-Ayadi Fatma, Sallemi Fahima, Ellouze-Chaabouni Semia, Ghribi-Aydi Dhouha
a Enzymes and Bioconversion Research Unit, National School of Engineers of Sfax (ENIS) , Sfax , Tunisia.
b Higher Institute of Biotechnology of Sfax (ISBS) , Sfax , Tunisia.
Arch Physiol Biochem. 2017 May;123(2):112-120. doi: 10.1080/13813455.2016.1261902. Epub 2016 Dec 25.
This study investigated the protective and the curative effects of Bacillus subtilis SPB1 crude lipopeptide biosurfactant in alleviating induced obesity complications in rats fed on high-fat-high-fructose diet (HFFD). Male Wistar rats were divided into five groups with the following treatment schedule: normal diet-fed rats (CD), HFFD-fed rats, HFFD-fed rats supplemented with SPB1 biosurfactant from the first day of the experiment (HFFD + Bios1), rats fed on HFFD receiving standard drug (HFFD + Torva), or SPB1 biosurfactant (HFFD + Bios2) during the last 4 weeks of the study. HFFD induced hyperglycemia, manifested by a significant (p < 0.001) increase (20%) in the levels of glucose and α-amylase activity in the plasma, when compared with CD. The administration of SPB1 biosurfactant to rats fed on HFFD reverted back normal blood glucose and α-amylase activity levels. Also, the findings clearly showed that acute oral administration of SPB1 biosurfactant reduced significantly (34%) the peak of blood glucose concentration 60 min after glucose administration, as compared with untreated rats fed on HFFD. Furthermore, renal dysfunction indices such as creatinine and urea as well as the level of angiotensin I-converting enzyme (ACE) exhibited remarkable increases in serum of rats fed on HFFD by 28.35%, 46%, and 92%,. Interestingly, SPB1 lipopeptides treatments decreased the creatinine and urea levels significantly (p < 0.001) near normal values, as compared with that of the HFFD group, and also showed an improvement of the kidney cortex architecture. Moreover, SPB1 biosurfactant displayed a potent inhibition of ACE activity in vitro (CI value=1.37 mg/mL) as well as in vivo in obese rats by 42% and 27.25% with HFFD + Bios1 and HFFD + Bios2 treatments, respectively, and comparatively with the HFFD group. Besides, SPB1 lipopeptides treatments improved some of serum electrolytes such as Na, K, Ca, and Mg. The results showed that SPB1 lipopeptide biosurfactant presented useful hypoglycemic and antihypertensive properties, and was able to alleviate renal lipid deposition in rats fed on a hypercaloric diet.
本研究调查了枯草芽孢杆菌SPB1粗脂肽生物表面活性剂对高脂高果糖饮食（HFFD）喂养的大鼠诱导性肥胖并发症的保护和治疗作用。雄性Wistar大鼠分为五组，采用以下治疗方案：正常饮食喂养的大鼠（CD）、HFFD喂养的大鼠、从实验第一天开始补充SPB1生物表面活性剂的HFFD喂养的大鼠（HFFD + Bios1）、在研究的最后4周接受标准药物（HFFD + Torva）或SPB1生物表面活性剂（HFFD + Bios2）的HFFD喂养的大鼠。与CD组相比，HFFD诱导了高血糖，表现为血浆中葡萄糖水平和α-淀粉酶活性显著（p < 0.001）升高（20%）。给HFFD喂养的大鼠施用SPB1生物表面活性剂可使血糖和α-淀粉酶活性水平恢复正常。此外，研究结果清楚地表明，与未治疗的HFFD喂养大鼠相比，急性口服SPB1生物表面活性剂可使葡萄糖给药后60分钟时的血糖浓度峰值显著降低（34%）。此外，高脂高糖饮食喂养的大鼠血清中的肌酐、尿素等肾功能障碍指标以及血管紧张素I转换酶（ACE）水平分别显著升高28.35%、46%和92%。有趣的是，与HFFD组相比，SPB1脂肽治疗使肌酐和尿素水平显著降低（p < 0.001）至接近正常水平，并且还显示出肾皮质结构的改善。此外，SPB1生物表面活性剂在体外（CI值 = 1.37 mg/mL）以及在肥胖大鼠体内均表现出对ACE活性的有效抑制，HFFD + Bios1和HFFD + Bios2治疗组分别比HFFD组抑制了42%和27.25%。此外，SPB1脂肽治疗改善了一些血清电解质，如钠、钾、钙和镁。结果表明，SPB1脂肽生物表面活性剂具有有用的降血糖和降压特性，并且能够减轻高热量饮食喂养的大鼠的肾脏脂质沉积。
